药物基因组学对肠易激综合征管理的影响
本综述回顾药物基因组学在肠易激综合征(IBS)常用药物代谢中的作用,重点为细胞色素P450代谢,并举例说明受体或中间通路的遗传变异及精准医学对IBS医疗的影响。药物基因组学同时影响药代动力学和药效动力学;尽管大型临床试验尚未纳入可影响IBS药物疗效的遗传变异检测,但个体患者纳入药物基因组学检测具有治疗优势,尤其在精神科中枢神经调节剂治疗中已得到证明。IBS临床实践正借助针对药物代谢的商用检测朝同一方向发展;IBS病理生理机制相对癌症和炎症性肠病仍表征不足,因此与药效动力学相关的药物基因组学仍处于起步阶段,需要大量未来研究。
要点
- 药物基因组学同时影响IBS药物的药代动力学和药效动力学。
- 大型临床试验尚未纳入可影响IBS药物疗效的遗传变异检测。
- 个体患者纳入药物基因组学检测具有治疗优势,精神科中枢神经调节剂治疗已证明。
核心结论
- 药物基因组学影响IBS药物的药代动力学和药效动力学,个体患者纳入药物基因组学检测具有治疗优势。
- IBS临床实践正借助针对药物代谢的商用检测朝精准医学方向发展。
- 与药效动力学相关的药物基因组学仍处于起步阶段,需要大量未来研究。
研究设计与样本
- 综述,回顾药物基因组学在IBS常用药物代谢中的作用,重点为细胞色素P450代谢。
- 其他目的为举例说明IBS药物靶点受体或中间通路的遗传变异,并批判性评价精准医学影响IBS健康的情景。
主要发现
- 药物基因组学同时影响药代动力学和药效动力学。
- 大型临床试验尚未纳入可影响IBS药物疗效的遗传变异检测。
- 个体患者纳入药物基因组学检测具有治疗优势,尤其在精神科中枢神经调节剂治疗中已得到证明。
- IBS病理生理机制相对癌症和炎症性肠病仍表征不足,因此与药效动力学相关的药物基因组学仍处于起步阶段,需要大量未来研究。
临床怎么用
- IBS临床实践正借助针对药物代谢的商用检测朝精准医学方向发展。
- 个体患者纳入药物基因组学检测具有治疗优势,尤其在精神科中枢神经调节剂治疗中已得到证明。
局限性
- 大型临床试验尚未纳入可影响IBS药物疗效的遗传变异检测。
- IBS病理生理机制相对癌症和炎症性肠病仍表征不足,因此与药效动力学相关的药物基因组学仍处于起步阶段,需要大量未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objectives are to review the role of pharmacogenomics in drug metabolism of medications typically used in patients with irritable bowel syndrome (IBS) focusing predominantly on cytochrome P450 metabolism. Other aims are to provide examples of genetic variation of receptors or intermediary pathways that are targets for IBS drugs and to critically appraise the situations where precision medicine is impacting health in IBS. Pharmacogenomics impacts both pharmacokinetics and pharmacodynamics. Although large clinical trials have not incorporated testing for genetic variations that could impact the efficacy of medications in IBS, there are therapeutic advantages to inclusion of pharmacogenomics testing for individual patients, as has been demonstrated particularly in the treatment with central neuromodulators in psychiatry practice. Clinical practice in IBS is moving in the same direction with the aid of commercially available tests focused on drug metabolism. Specific mechanisms leading to pathophysiology of IBS are still poorly characterized, relative to diseases such as cancer and inflammatory bowel disease, and, therefore, pharmacogenomics related to drug pharmacodynamics is still in its infancy and requires extensive future research. With increased attention to pharmacogenomics affecting drug metabolism, it is anticipated that pharmacogenomics will impact care of IBS.
引用
- Camilleri M. Implications of Pharmacogenomics to the Management of IBS. Clin Gastroenterol Hepatol. 2018. PMID: 29709540. doi:10.1016/j.cgh.2018.04.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。